But these enzymes are also known to mutate other cells' DNA sometimes. This research has determined that chemotherapy can be ...

Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for ...

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

a global Phase 3 study evaluating radiotherapy-activated NBTXR3 for patients with head and neck cancer ineligible for cisplatin, from Nanobiotix to Janssen. Nanobiotix has transferred the sponsorship ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF ® (bupivacaine and meloxicam) extended-release ...